Hyponatremia in kidney transplant patients: its pathophysiologic mechanisms

Carlos G. Musso1,2, Alejandrina Castañeda1, María Giordani1,2, Cesar Mombelli2, Silvia Groppa2, Nora Imperiali1,2 and Guillermo Rosa Diez2

1Human Physiology Department, Instituto Universitario del Hospital Italiano de Buenos Aires, Buenos Aires, Argentina and 2Nephrology Division, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Correspondence and offprint requests to: Carlos G. Musso; E-mail: carlos.musso@hospitalitaliano.org.ar

ABSTRACT

Kidney transplant patients (KTPs), and particularly those with advanced chronic kidney rejection, may be affected by opportunistic infections, metabolic alterations and vascular and oncologic diseases that promote clinical conditions that require a variety of treatments, the combinations of which may predispose them to hyponatremia. Salt and water imbalance can induce abnormalities in volemia and/or serum sodium depending on the nature of this alteration (increase or decrease), its absolute magnitude (mild or severe) and its relative magnitude (body sodium:water ratio). Hyponatremia appears when the body sodium:water ratio is reduced due to an increase in body water or a reduction in body sodium. Additionally, hyponatremia is classified as normotonic, hypertonic and hypotonic and while hypotonic hyponatremia is classified in hyponatremia with normal, high or low extracellular fluid. The main causes of hyponatremia in KTPs are hypotonic hyponatremia secondary to water and salt contraction with oral hydration (gastroenteritis, sepsis), free water retention (severe renal failure, syndrome of inappropriate antidiuretic hormone release, hypothyroidism), chronic hypokalemia (rapamycin, malnutrition), sodium loss (tubular dysfunction secondary to nephrocalcinosis, acute tubular necrosis, tubulitis/rejection, interstitial nephritis, adrenal insufficiency, aldosterone resistance, pancreatic drainage, kidney–pancreas transplant) and hyponatremia induced by medication (opioids, cyclophosphamide, psychoactive, potent diuretics and calcineurinic inhibitors). In conclusion, KTPs are predisposed to develop hyponatremia since they are exposed to immunologic, infectious, pharmacologic and oncologic disorders, the combinations of which alter their salt and water homeostatic capacity.

Keywords: hyponatremia, immunosuppressant, kidney transplant, low serum sodium, pathophysiology

INTRODUCTION

Renal transplantation is currently the most effective treatment for patients with end-stage renal disease [1]. However, this group of patients, and particularly those with advanced chronic kidney rejection, are sometimes affected by opportunistic infections, metabolic alterations and vascular and oncologic diseases that require treatments, the combination of which predisposes them to hyponatremia [2]. Hyponatremia is considered an important risk factor for high morbidity and mortality because it can decrease brain function, compromise cardiac contractility, increase insulin resistance and induce neuromuscular dysfunction. Han et al. [3] documented that hyponatremia is related in kidney transplant patients (KTPs) to overall mortality and graft loss, although it had

Received: 1.11.2017. Editorial decision: 18.1.2018

© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Hyponatremia Prevalence Clinical relevance Treatment
Normotonic – – –
Intravenous immunoglobulin High Low Resolves after stopping drug
Hypertonic – – –
Hyperglycemia High Low Glycemic control
Hypotonic with low ECF – – –
Renal sodium loss (rejection, diuretics) High High Sodium replacement and treat cause
Extrarenal sodium loss (diarrhea) High High Sodium replacement and treat cause
Adrenal insufficiency High High Hormone replacement
Immunosuppressant drugs High High Fluids and electrolyte therapy
Hypotonic with high ECF – – –
Heart failure Low High Salt and water restriction/diuretics
Cirrhosis Low High Salt and water restriction/diuretics
Nephrotic syndrome High High Salt and water restriction/diuretics/treat cause
Renal insufficiency High High Salt and water restriction/diuretics/dialysis treat cause
Hypotonic with normal ECF – – –
SIADH High High Water restriction/diuretics
Hypothyroidism Low Low Hormone replacement
Glucocorticoid deficiency Low High Hormone replacement
Psychoactive drugs High Low Replace drug

no correlation with acute rejection. Thus serum sodium should be monitored posttransplant in order to prepare physicians for potentially poorer outcomes. Moreover, pediatric kidney transplant recipients are at a significantly higher risk than adults for developing hyponatremic encephalopathy and death associated with serum sodium levels ≤120 mmol/L, thus meticulous postoperative fluid management is exceptionally important to minimize the risk of neurologic complications in this population [4]. Salt and water imbalance can induce abnormalities in volemia and/or serum sodium depending on the nature of this alteration, its absolute magnitude and how they alter the relative body sodium:water ratio [5]. It is known that significant salt and water depletion may generate real hypovolemia, and if this depletion involves a loss of salt in excess of water it may generate hyponatremia [3]. Also, salt and water retention induces an increase in extracellular fluid (ECF) that, depending on its pathophysiologic mechanism, may occur with hypervolemia and edema (e.g. hyponatremia in immediate posttransplant anuric patient) or effective arterial hypovolemia and edema (hyponatremia in a KTP suffering from cirrhosis secondary to hepatitis C virus or hyponatremia secondary to posttransplant nephrotic syndrome most frequently induced by focal and segmental glomerular sclerosis or membranoproliferative glomerulonephritis) [5, 6]. The sodium:water ratio can also be modified by body potassium content since its intracellular depletion induces low serum sodium levels by at least two mechanisms [5]: a shift of sodium to the intracellular compartment and by inappropriate antidiuretic hormone release.

This concept is summarized by the Edelman equation [5]: serum sodium = body (exchangeable) sodium + body (exchangeable) potassium/total body water. For instance, hyponatremia secondary to hypokalemia in KTPs on rapamycin, loop diuretics (e.g. furosemide) or suffering from renal tubular acidosis (primary or secondary to graft rejection) [7–12]. Additionally, two infrequent causes of hyponatremia in KTPs should be mentioned: first, a low serum sodium level due to excessive water intake (>14 L/day), which overcomes the free water reexcretion capacity of the kidneys and characteristically occurs with suppressed antidiuretic hormone and low osmolar urine [1, 5]; second, a reset osmostat hyponatremia, which can be observed in malnourished chronically ill KTPs [5]. Based on the above-mentioned pathophysiological mechanisms, hyponatremia is currently classified depending on the patient’s plasma tonicity level as hypertonic, normotonic or hypotonic hyponatremia. In addition, hypotonic hyponatremia is classified depending on the patient’s ECF status as low, normal or high ECF [5]. It is worth mentioning that hyponatremia in KTPs usually results from a combination of hyponatremia-inducing mechanisms. All the hyponatremia-inducing mechanisms in KTPs that are described here are summarized in Table 1 along with their prevalence and clinical significance [3, 4, 7, 10–12].

HYPONATREMIA
Normotonic hyponatremia
Normotonic hyponatremia is an artifact due to an increase in the solid fraction of plasma, which can be documented in KTPs who received intravenous (IV) immunoglobulin (hypersensitive patients) or in those who have severe hypergammaglobulinemia secondary to hepatitis C [13–19]. It is worth mentioning that it is important to identify pseudo-hyponatremia because treating this entity as hypotonic hyponatremia may lead to dehydration [16, 17]; a direct ion-sensitive electrode potentiometry-based estimation can avoid this mistake [20].

Hypertonic hyponatremia
Hyperglycemia increases extracellular tonicity and extracts free water out of the intracellular compartment, diluting the extracellular compartment and consequently inducing hyponatremia [3]. Thus this sort of hyponatremia can be observed in a setting of drug-induced diabetes mellitus decompensation (high doses of methylprednisolone, high serum levels of calcineurin inhibitors or a combination of both drugs), sepsis in kidney transplant diabetic patients (predisposed by immunosuppressant treatment) or pancreas graft rejection in kidney–pancreas transplant patients [20–22]. Additionally, even though hyponatremia induced by IV immunoglobulin has been interpreted as a pseudo-hyponatremia, other reports have documented that this
therapy can result in true hyponatremia, resulting from sucrose-induced translocation of water from the intracellular compartment to the extracellular compartment, as well as a large volume of hypotonic fluid in patients who have altered urinary free water excretion [14].

**Hypotonic hyponatremia**

Hypotonic hyponatremia can be induced by an excess of water, impaired free water urine excretion because of reduced fluid delivery (heart failure) to the thick ascending limb of the loop of Henle (TALH), altered TALH segment function (tubular necrosis or inflammation), inappropriate or inappropriately antidiuretic hormone release or a combination of these [5]. Thus patients with lung (pneumonia, etc.), cardiac (cardiac failure), kidney (renal insufficiency), hepatic (cirrhosis), endocrine (hypothyroidism, adrenal insufficiency) and encephalic diseases (psychiatric disorders, syndrome of inappropriate antidiuretic hormone release (SIADH), cerebral salt wasting syndrome) can develop hypotonic hyponatremia [5].

**Normal ECF hyponatremia.** SIADH. SIADH is a condition induced by inappropriate free water retention because of inappropriate antidiuretic hormone release or an excessive response of vasopressin receptors in the distal tubules in a setting of normal glomerular filtration rate, thyroid and adrenal function and no hyponatremia-inducing medication [5]. SIADH has been described in this population as secondary to infection (tuberculosis, etc.), mainly in the central nervous system (cerebral nocardiosis, etc.) [23–25]. Other mechanisms of hyponatremia with normal ECF that should be taken into account in this population are hypothyroidism-induced hyponatremia and glucocorticoid deficiency-induced hyponatremia.

**Hypothyroidism-induced hyponatremia.** Hypothyroidism can induce low serum sodium levels by different mechanisms: renal hypoperfusion due to heart failure, inappropriate vasopressin secretion and high sodium loss in urine [26–32]. It worth mentioning that it should rule out in persistently hyponatremic-immunosuppressed individuals the presence of a hypothyroidism secondary to a decrease in hypothalamic thyrotropin-releasing hormone (TRH) induced by a masked wasting syndrome [32, 33].

**Glucocorticoid deficiency–induced hyponatremia.** Cortisol exerts a negative effect on antidiuretic hormone secretion, thus a cortisol deficit can promote inappropriate antidiuretic hormone release, in turn increasing the risk of developing hyponatremia [5]. The isolated cortisol deficit can be induced by any glucocorticoid axis damage [34].

**Low ECF hyponatremia.** Hypovolemia may induce low serum sodium levels by stimulating nonsomotic antidiuretic hormone release in a setting of adequate or excessive oral water intake [5]. Sodium losses lead to volume depletion inducing adequate antidiuretic hormone secretion. Thus low serum sodium level is promoted by two mechanisms: sodium loss and water retention. Moreover sodium loss is worsened when there is reduced renin–angiotensin–aldosterone system (RAAS) activity (e.g. tubular damage or adrenal failure) [5].

Pancreatic sodium loss. Low ECF hyponatremia is common in pancreas–kidney transplant patients and is usually attributed to sodium loss in the pancreatic exocrine secretion drained in the bladder [21]. Genitourinary tract (GT) drainage compared with the alternatives (pancreatic duct ligation or enteric drainage) is less prone to develop pancreatitis or microbial contamination, respectively, and also provides the opportunity to monitor urine pH and amylase levels for detecting pancreas rejection. However, GT drainage may induce cystitis, balanitis and/or hyperchloremic metabolic acidosis and hyponatremia secondary to increased sodium bicarbonate urinary loss [21, 22, 35]. At least two pathophysiological mechanisms have been postulated for this sort of hyponatremia: total body sodium depletion through urinary volume and altered free water clearance secondary to renal failure. In this setting, hyponatremia usually gets worst if the kidney is simultaneously suffering from tubular damage (necrosis, rejection, etc.) and therefore is unable to maximally conserve sodium [22].

**Massive posttransplant polyuria.** Polyuria after kidney transplantation is not a rare condition, but massive polyuria is not common [34]. This entity can lead to significant sodium wasting and consequently to hyponatremia, and eventually to cerebral edema and seizure activity [26]. This sodium loss is secondary to tubular dysfunction induced by hypoxic-ischemic graft injury and aldosterone resistance in a context of a rapid normalization of the glomerular filtration rate [26, 36]. In these cases, the high fractional excretion of sodium reported in the graft urine is characteristically associated with ischemic changes on the graft biopsy [26].

**Sodium-losing nephropathy.** Altered tubular function in the transplanted kidney is common (more so in cadaveric donors than in living donors) and most is ascribed to tubular necrosis or graft rejection; this can improve if the acute process resolves. Other proposed pathophysiological mechanisms are the presence of RAAS resistance, graft nephrocalcinosis (tubular necrosis or rejection) or a carryover effect of pre-transplantation ‘third factor’. Sodium-losing nephropathy is characterized by severe sodium loss (fractional excretion of sodium ~38%) with nonoliguric (neither polyuric) renal failure that responds to large amounts of normal saline and a high sodium diet but not to mineralocorticoid therapy [36].

**Fanconi syndrome (FS).** FS is another source of urine sodium loss inducing hyponatremia. FS can appear in children or adult transplant patients who have received a cadaveric or living donor kidney. FS can be induced by hyperparathyroidism, tubular disease or rejection [8, 37–41].

**Adrenal insufficiency.** The hypothalamic–pituitary–adrenal axis (HPAA) can be activated by severe illness and trauma, since HPAA controls the maintenance of homeostasis and general adaptation to stress by increasing corticotropin and cortisol serum concentrations. However, in KTPs on chronic corticoid therapy, adrenal gland function is suppressed due to exogenous steroids and cannot resume steroid synthesis. Thus, relative adrenal insufficiency must be considered in patients who have received prolonged glucocorticoid therapy and have symptoms such as hypotension and/or hyponatremia, even in the context of normal serum cortisol levels, since they can be relatively low [42, 43].

**High ECF hyponatremia.** This condition is observed in KTPs when they are suffering from severe edematous status, which could be secondary to nephrotic syndrome, and renal, heart or liver failure. In these settings of effective hypovolemia, low
Drug-induced hyponatremia. Drug-induced hyponatremia is one of the main causes of hyponatremia in KTPs and therefore this type of hyponatremia is described here separately [5]. Medication can induce hyponatremia by different mechanisms that promote water retention and/or sodium loss (Table 2) [7, 22, 38, 45–49]. High-dose IV cyclophosphamide (30–50 mg/kg), opioids and psychoactive drugs, which are usually used in treatment in transplant patients, and also the ineffectiveness of calcineurinic inhibitors (tacrolimus and cyclosporine), studies have suggested that cyclosporine reduces proximal tubular sodium reabsorption by decreasing sodium–hydrogen exchanger activity, which is responsible for reabsorbing 30–60% of the filtered sodium, while tacrolimus has a more profound effect on distal tubular function, where it alters tubular sodium handling, which is responsible for aldosterone resistance, and can cause salt-losing nephropathy [21, 47, 49–51]. This phenomenon explains why hyponatremia was reported as significantly more common under tacrolimus therapy than cyclosporine in renal transplantation patients on sirolimus and calcineurin inhibitors. Prevention in Renal Disease 2009; 2: 1–4

CONCLUSION

KTPs are predisposed to develop hyponatremia since they are exposed to immunologic, infectious, pharmacologic and oncologic disorders, the combination of which alters their salt and water homeostatic capacity.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Carrasco FR, Moreno A, Ridao N et al. Kidney transplantation complications related to psychiatric or neurological disorders. Transplant Proc 2009; 41: 2430–2432
2. Danovitch G. Handbook of Kidney Transplantation. Boston: Little, Brown, 1996
3. Han SS, Han M, Park JY et al. Posttransplant hyponatremia predicts graft failure and mortality in kidney transplantation recipients: a multicenter cohort study in Korea. PLoS One 2016; 11: e0156050
4. Drake K, Nehrus E, Goeke J. Hyponatremia, hypo-osmolality, and seizures in children early post-kidney transplant. Pediatr Transplant 2015; 19: 698–703
5. Adrogue H, Wesson D. Salt & Water. Houston: Libra & Gemini, 1993
6. Ponticelli C, Glassock R. Treatment of Primary Glomerulonephritis. Oxford: Oxford University Press, 2009
7. Lacy C, Armstrong L, Goldman M et al. Drug Information Handbook. Hudson, OH: Lexicomp, 2004
8. Briggs WA, Kominami N, Wilson RE et al. Kidney transplantation in Fanconi syndrome. N Engl J Med 1972; 286: 25
9. Friedman A, Chesney R. Fanconi’s syndrome in renal transplantation. Am J Nephrol 1981; 1: 45–47
10. Giordani C, Musso CG, Groppa R et al. Renal reserve in kidney transplant patients on sirolimus and calcineurin inhibitors. Prevention in Renal Disease 2009; 2: 1–4
11. Groth CG, Bäckman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036–1042
12. Morales JM, Wramner L, Kreis H et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant. 2002; 2: 436–442
13. Lawn N, Wijdicks EF, Burritt MF. Intravenous immune globulin and pseudo-hyponatremia. N Engl J Med 1998; 339: 632
14. Nguyen MK, Rastogi A, Kurtz I. True hyponatremia secondary to intravenous immunglobulin. Clin Exp Nephrol 2006; 10: 124–126
15. Fabrizi F, Dixit V, Messa P. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies. J Med Virol 2013; 85: 1019–1027
16. Rodriguez-Castro KI, Morisco F, Rigotti P et al. Hepatitis C virus infection in end stage renal disease and after kidney transplant. J Gastrointestin Liver Dis 2014; 23: 340–342
17. Korkmaz M, Faki S, Öcal S et al. Progression of hepatic histopathology in kidney transplant recipients with chronic hepatitis C virus infection and effect of immunosuppression on the course of hepatitis C virus infection. Exp Clin Transplant 2015; 13(Suppl 1): 159–164
18. Edelman IS, Leibman J, O’Meara MP et al. Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water. J Clin Invest 1958; 37: 1236–1256
19. Garibiardi BT, Cameron SJ, Choi M. Pseudo-hyponatremia in a patient with HIV and hepatitis C coinfection. J Gen Intern Med 2008; 23: 202–205
20. Bevilacqua M. Hyponatraemia in AIDS. Baillieres Clin Endocrinol Metab 1994; 8: 837–848
21. Bagchi S, Husain Zaied S, Prasad Mathur R. Severe symptomatic hyponatremia—an uncommon presentation of tacrolimus nephrotoxicity. Nephrol Dial Transplant 2011; 26: 2042–2044
22. Higgins R, Ramaiyan K, Dasgupta T et al. Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. Nephrol Dial Transplant 2004; 19: 444–450.

23. Srinivas KV, Freigoun OS, Rabie A et al. Cerebral nocardiosis in a renal transplant recipient: a case report. Saudi J Kidney Dis Transpl 2000; 11: 583–586.

24. Delgado S, Durán MI. Encephalitis in a renal transplantation patient. Neurologia 2004; 24(Suppl 3): 21–25.

25. Motiwala HG, Sanghvi NP, Barjatiya MK et al. Syndrome of inappropriate antidiuretic hormone following tuberculosis epididymo-orchitis in renal transplant recipient: case report. J Urol 1991; 146: 1366–1367.

26. Cansick J, Rees L, Koffman G et al. A fatal case of cerebral oedema with hyponatraemia and massive polyuria after renal transplantation. Pediatr Nephrol 2009; 24: 1231–1234.

27. Makino Y, Fujii T, Kuroda S et al. Exacerbation of renal failure due to hypothyroidism in a patient with ischaemia nephropathy. Nephron 2000; 84: 267–269.

28. Cadnapaphornchai MA, Kim YW, Gurevich AK et al. Urinary concentrating defect in hypothyroid rats: role of sodium, potassium, 2-chloride co-transporter, and aquaporins. J Am Soc Nephrol 2003; 14: 566–574.

29. Woodrow G, Brownjohn AM, Turney JH. Acute-on-chronic renal failure and hyponatraemia associated with severe hypothyroidism. Nephrol Dial Transplant 1993; 8: 557–559.

30. Schmitt R, Klussmann E, Kahl T et al. Renal expression of sodium transporters and aquaporin-2 in hypothyroid rats. Am J Physiol 2003; 284: F1097–1104.

31. Shah M, Quigley R, Baum M. Maturation of proximal straight tubule NaCl transport: role of thyroid hormone. Am J Physiol Renal Physiol 2000; 278: F596–F602.

32. Musso CG, Macías Núñez JF, Imperiali N et al. Low fractional excretion of urea in hypothyroidism induced hyponatraemia. Electron J Biomed 2005; 1: 64–67.

33. Carta S, Olivier A, Sorcini M et al. Endocrine response to HIV infection. Involvement of thyroid gland. Ann Ist Super Sanita 1993; 29: 451–456.

34. Schafer JA. Renal water reabsorption: a physiologic retrospective in a molecular era. Kidney Int 2004; 66(Suppl 91): S20–S27.

35. Rabb HA, Niles JL, Cosimi AB et al. Severe hyponatraemia associated with combined pancreatic and renal transplantation. Transplantation 1989; 48: 157–159.

36. Hoang TD, Bao VQ, Phat VH. Massive polyuria after kidney transplantation. Pediatr Nephrol 2010; 25: 383–384.

37. Ferguson RK, Reed DM, Barber KG et al. Sodium-losing nephropathy and nephrocalcinosis after transplantation. Am J Kidney Dis 1985; 5: 206–2010.

38. Daphnis E, Stylianou K, Alexandrakis M et al. Acute renal failure, translocational hyponatraemia and hyperkalaemia following intravenous immunoglobulin therapy. Nephron Clin Pract 2007; 106: c143–c148.

39. Heering P, Degenhardt S, Grabeen S. Tubular dysfunction following kidney transplantation. Nephron 1996; 74: 501–511.

40. Câmara NO, Silva MS, Nishida S et al. Proximal tubular dysfunction is associated with chronic allograft nephropathy and decreased long-term renal-graft survival. Transplantation 2004; 78: 269–275.

41. Sanjad SA, Ibrahim A, Al Shorafa S et al. Renal tubular dysfunction following kidney transplantation: a prospective study in 51 children. Transplant Proc 2001; 33: 2830–2831.

42. Cinclaire RD, Rice JC, Agraharkar M. Relative adrenal insufficiency in post-transplant lymphoproliferative disorder. J Postgrad Med 2003; 49: 69–71.

43. Bromberg JS, Alfrey EJ, Barker CF et al. Adrenal suppression and steroid supplementation in renal transplant recipients. Transplantation 1991; 51: 385–390.

44. Ghorbani A, Feli M, Ehsanpour A et al. Half-saline versus combined normal saline and 1/3–2/3 intravenous fluid therapy in kidney transplantation. Int J Organ Transplant Med 2011; 2: 101–104.

45. Berl T, Schrier R. Water homeostasis disorders. In: Schrier R (ed.). Renal and Electrolyte Disorders. Philadelphia: Williams & Wilkins, 2011, 1–44.

46. Sran H, Phanish MK. Confusion after starting citalopram in a renal transplant patient. BMJ Case Rep 2013; doi: 10.1136/bcr-2013-010511.

47. Burdmann E, Bennett W. Nephrotoxicity of calcineurin and mTOR inhibitors. In: De Broe M, Porter G, Bennett W et al. (eds). Clinical Nephrotoxins. Renal Injury from Drugs and Chemicals. New York: Springer, 2008, 617–682.

48. Donadio C, Puccini R, Acquarica M. Relative adrenal insufficiency in post-transplant lymphoproliferative disorder. Transplant Proc 1998; 30: 2036–2037.

49. Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide. Arch Intern Med 1985; 145: 548–549.

50. Musso CG, Navarro M, Mombelli C et al. Furosemide test in stage III-chronic kidney disease and kidney transplant patients on tacrolimus. Int Urol Nephrol 2013; 45: 1471–1474.

51. Einollahi B, Nemati E, Rostami Z et al. Electrolytes disturbance and cyclosporine blood levels among kidney transplant recipients. Int J Organ Transplant Med 2012; 3: 166–175.